Seres Therapeutics, Inc. (MCRB) financial statements (2021 and earlier)

Company profile

Business Address 200 SIDNEY STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:2549586150230205
Cash and cash equivalents1166586365574
Short-term investments13830 114139131
Other undisclosed cash, cash equivalents, and short-term investments    37 
Receivables92    
Other undisclosed current assets6475(32)3
Total current assets:26910093155198208
Noncurrent Assets
Operating lease, right-of-use asset911
Property, plant and equipment14192633368
Long-term investments and receivables50   37 
Long-term investments50   37 
Restricted cash and investments112212
Total noncurrent assets:74322834749
TOTAL ASSETS:343132120190273217
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12101516159
Accounts payable456785
Accrued liabilities113441
Employee-related liabilities755543
Deferred revenue 5
Debt04    
Contract with customer, liability20
Other undisclosed current liabilities3427716151
Total current liabilities:464642323011
Noncurrent Liabilities
Long-term debt and lease obligation3540    
Long-term debt, excluding current maturities2525    
Operating lease, liability1116
Liabilities, other than long-term debt1511932 
Deferred revenue and credits22 
Deferred revenue 5
Contract with customer, liability117
Deferred rent credit  2
Other liabilities1101  
Other undisclosed noncurrent liabilities86897941071
Total noncurrent liabilities:122135126971101
Total liabilities:16818116912914012
Stockholders' equity
Stockholders' equity attributable to parent175(48)(48)61133205
Common stock000000
Additional paid in capital723411341324307288
Accumulated other comprehensive income (loss)(0)  (0)(0)0
Accumulated deficit(549)(460)(389)(264)(174)(83)
Total stockholders' equity:175(48)(48)61133205
TOTAL LIABILITIES AND EQUITY:343132120190273217

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenue, net3222 
Revenue from related parties  27
Gross profit:3335283222 
Operating expenses(121)(106)(129)(123)(115)(55)
Operating loss:(88)(72)(100)(91)(93)(55)
Nonoperating income (expense)(1)21210
Investment income, nonoperating11    
Other nonoperating income1100  
Interest and debt expense(0)(1)  (1)(1)
Net loss:(90)(71)(99)(89)(93)(55)
Other undisclosed net income attributable to parent01  11
Net loss available to common stockholders, diluted:(89)(70)(99)(89)(92)(55)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(90)(71)(99)(89)(93)(55)
Other comprehensive income (loss)   0(0)0
Comprehensive loss:(90)(71)(99)(89)(93)(55)
Other undisclosed comprehensive income, net of tax, attributable to parent010 11
Comprehensive loss, net of tax, attributable to parent:(89)(70)(99)(89)(92)(55)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: